X4 Pharmaceuticals, Inc.
XFOR
$3.58
$0.082.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 20.18% | 15.40% | 19.76% | -15.83% | -9,228.01% |
| Total Depreciation and Amortization | 347.09% | 0.00% | 0.00% | -37.18% | -25.42% |
| Total Amortization of Deferred Charges | 3.91% | 11.11% | -6.33% | 4.25% | -5.78% |
| Total Other Non-Cash Items | 10.73% | 6.16% | 13.69% | 515.22% | 94.85% |
| Change in Net Operating Assets | -262.65% | -143.71% | 1,010.56% | 85.60% | -28.29% |
| Cash from Operations | -6.07% | -26.23% | 44.19% | 6.95% | -141.76% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -105.19% | 14.26% | 158.77% | -224.04% | 836.52% |
| Cash from Investing | -105.19% | 14.26% | 158.77% | -224.04% | 836.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,650.00% | -100.00% | 68.11% | 1,443.33% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3,650.00% | -100.00% | 68.11% | 1,443.33% | -- |
| Foreign Exchange rate Adjustments | 75.00% | -766.67% | 400.00% | -100.72% | 93.06% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5,850.14% | -100.25% | 384.72% | 3,084.59% | 93.40% |